Therefore, testing for BCR-ABL mutations in CD34+ CML stem/progenitor cells using validated sensitive assays like allele-specific PCR may be cost-effective and should be considered before the start of TKI therapy, particularly in patients who present in the late CP. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.